$A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma$

A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

On the basis of preclinical evidence of synergistic activity between MEK and EGFR inhibitors in pancreatic ductal adenocarcinoma (PDAC), we evaluated the safety and efficacy of selumetinib, a MEK1/2 inhibitor, plus erlotinib in patients with previously treated advanced PDAC. In this single-arm phase...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-01, Vol.22 (1), p.61-68
Hauptverfasser:	Ko, Andrew H, Bekaii-Saab, Tanios, Van Ziffle, Jessica, Mirzoeva, Olga M, Joseph, Nancy M, Talasaz, AmirAli, Kuhn, Peter, Tempero, Margaret A, Collisson, Eric A, Kelley, R Kate, Venook, Alan P, Dito, Elizabeth, Ong, Anna, Ziyeh, Sharvina, Courtin, Ryan, Linetskaya, Regina, Tahiri, Sanaa, Korn, W Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzimidazoles - administration & dosage Biomarkers DNA, Neoplasm - blood Drug Resistance, Neoplasm Erlotinib Hydrochloride - administration & dosage Female Humans Kaplan-Meier Estimate Male Middle Aged Molecular Targeted Therapy Neoplasm Staging Neoplastic Cells, Circulating Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Retreatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!